November 8, 2023 02:28 PM EST
Pharma

Gilead’s HIV sales hit $4.7B in Q3, first six-month PrEP ap­proval planned in 2025

Katherine Lewin

News Reporter

Gilead says it’s gain­ing clin­i­cal mo­men­tum with plans to grow its HIV fran­chise and nab an ap­proval for an every-six-month pre-ex­po­sure pro­phy­lax­is (PrEP) ap­proval. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times